Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory ...

In a report released on March 21, David Evans from Kepler Capital maintained a Buy rating on Novartis AG (NOVN – Research Report), with a ...

Pharming has agreed a deal to sell a recently awarded priority review voucher (PRV) to Novartis for around $21 million - well below the market rate. The price of PRVs, which can be used to shorten ...

EAST HANOVER, NJ, USA I March 20, 2025 I Novartis today announced that oral Fabhalta® (iptacopan) has received U.S. Food and Drug Administration (FDA) ...

TOKYO, March 17 (Reuters) - Swiss pharmaceutical giant Novartis (NOVN.S), opens new tab will watch "very carefully" how the reciprocal tariff policy proposed by the United States unfolds in early ...

A federal court rejected Novartis Pharmaceuticals’, a unit of Novartis AG (NYSE:NVS) legal challenge to the Medicare Drug Price Negotiation Program, ruling that the program does not violate ...

Basel: Novartis has announced that the U.S. Food and Drug Administration (FDA) has approved oral Fabhalta (iptacopan) for the ...

Our product reviews offer independent views with hands-on opinion and honest verdicts aimed to give you all the important information you need to make the best buying decisions.

Novartis AG (NYSE:NVS) announced safety and efficacy results from the Phase 3 program for investigational intrathecal ...

Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved ...

TOKYO (Reuters) -Swiss pharmaceutical giant Novartis says it is watching "very carefully" how the reciprocal tariff policy proposed by the United States would unfold in early April, Chief ...